Table 5 Correlation between sexual dysfunction prevalence in patients and their rheumatoid arthritis characteristics

 Mean ± SD.

3.7 ± 1.6

9.8 ± 5.4

U = 1654.0^*

< 0.001^*

5.7 ± 4.5

12.4 ± 6.6

U = 286.0^*

< 0.001^*

 Median (min.–max.)

4.0 (2.0–8.0)

9.0 (2.0–23.0)

4.0 (2.5–18.0)

10.0 (3.0–28.0)

 Mean ± SD.

2.6 ± 0.7

7.8 ± 9.7

U = 1416.0^*

< 0.001^*

2.1 ± 0.9

4.3 ± 1.8

U = 318.0*

< 0.001*

 Median (min.–max.)

1.5 (1.0–3.5)

5.5 (1.0–34.0)

2.0 (1.0–3.5)

4.5 (0.5–7.0)

 Mean ± SD.

3.7 ± 1.9

4.4 ± 3.8

U = 7090.0

0.783

3.1 ± 1.3

3.3 ± 2.5

U = 972.0

0.701

 Median (min.–max.)

3 (2–9)

3 (0–15)

3 (1–7)

3 (0–9)

 Mean ± SD.

4 ± 2.9

10.4 ± 5.7

U =2128.0^*

< 0.001^*

8.1 ± 4.7

6.5 ± 4.9

U = 823.0

0.118

 Median (min.–max.)

3 (1–10)

10 (2–21)

7 (2–19)

7 (0–17)

 Mean ± SD.

0.5 ± 0.7

1.7 ± 0.9

U =2250.0^*

< 0.001^*

0.6 ± 1.0

1.6 ± 1.1

U = 522.0^*

< 0.001^*

 Median (min.–max.)

0.0 (0.0–2.0)

2.0 (0.0–3.0)

0.0 (0.0–3.0)

2.0 (0.0–3.0)

 Mean ± SD.

26.4 ± 13.6

55.3 ± 21.5

U =2064.0^*

< 0.001^*

37.2 ± 28.8

42.6 ± 24

U = 853.0

0.188

 Median (min.–max.)

20 (10–55)

60 (20–90)

25 (10–89)

40 (10–90)

 No deformity

74 (78.7)

60 (39)

χ² = 92.39

< 0.001^*

23 (67.6)

29 (48.3)

χ² = 3.275

0.070

 Deformity

20 (21.3)

94 (61)

11 (32.4)

31 (51.7)

 Monotherapy

35(37.2)

8 (5.2)

χ² = 119.828^*

< 0.001^*

11 (32.3)

8 (13.3)

χ² = 27.586^*

< 0.001^*

 Ditherapy

26 (27.7)

52 (33.8)

14 (41.2)

12 (20)

 Triple therapy

18 (19.1)

52 (33.8)

5 (14.7)

20 (33.3)

 Biological therapy

15 (16.0)

42 (27.3)

4 (11.8)

20 (33.3)